HK1062294A1 - Compounds useful as intermediates for 4-aminoquinoline derivates - Google Patents

Compounds useful as intermediates for 4-aminoquinoline derivates

Info

Publication number
HK1062294A1
HK1062294A1 HK04105255A HK04105255A HK1062294A1 HK 1062294 A1 HK1062294 A1 HK 1062294A1 HK 04105255 A HK04105255 A HK 04105255A HK 04105255 A HK04105255 A HK 04105255A HK 1062294 A1 HK1062294 A1 HK 1062294A1
Authority
HK
Hong Kong
Prior art keywords
aminoquinoline
derivates
intermediates
compounds useful
compounds
Prior art date
Application number
HK04105255A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HK1062294A1 publication Critical patent/HK1062294A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK04105255A 2001-04-30 2004-07-19 Compounds useful as intermediates for 4-aminoquinoline derivates HK1062294A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30
PCT/IB2002/001217 WO2002088069A2 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatives

Publications (1)

Publication Number Publication Date
HK1062294A1 true HK1062294A1 (en) 2004-10-29

Family

ID=23103272

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04105255A HK1062294A1 (en) 2001-04-30 2004-07-19 Compounds useful as intermediates for 4-aminoquinoline derivates

Country Status (25)

Country Link
US (3) US6689897B2 (pt)
EP (2) EP1383734B1 (pt)
JP (2) JP3924250B2 (pt)
KR (2) KR100591998B1 (pt)
CN (3) CN1297541C (pt)
AR (3) AR036331A1 (pt)
AT (2) ATE316957T1 (pt)
AU (1) AU2002253448B2 (pt)
BR (2) BR0209291A (pt)
CA (2) CA2445623A1 (pt)
CZ (2) CZ20032898A3 (pt)
DE (2) DE60210265T2 (pt)
DK (2) DK1425270T3 (pt)
ES (2) ES2259080T3 (pt)
HK (1) HK1062294A1 (pt)
HU (2) HU225777B1 (pt)
IL (2) IL157546A0 (pt)
MX (2) MXPA03009936A (pt)
PL (2) PL366700A1 (pt)
PT (1) PT1425270E (pt)
RU (2) RU2259355C2 (pt)
TW (1) TWI250974B (pt)
WO (2) WO2002088069A2 (pt)
YU (2) YU84303A (pt)
ZA (2) ZA200306599B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US7601842B2 (en) 2003-02-18 2009-10-13 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
BRPI0407954A (pt) * 2003-03-17 2006-03-07 Kaneka Corp processo para a produção de derivado de amida de ácido (r)-3-[4-(trifluorometil) fenilamino]-pentanóico
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
US7749992B2 (en) * 2003-10-08 2010-07-06 Eli Lilly And Company Compounds and methods for treating dislipidemia
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
WO2005100321A1 (en) * 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1761521A1 (en) * 2004-06-24 2007-03-14 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
KR20070114762A (ko) 2005-02-24 2007-12-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
AR058007A1 (es) * 2005-06-20 2008-01-23 Astrazeneca Ab Proceso para la produccion de sulfonatos de (alcoxicarbonilamino) - alquilo
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
WO2008112166A2 (en) 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US9371294B2 (en) 2011-04-12 2016-06-21 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
SG10201605304VA (en) 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
CN105143193B (zh) 2013-01-31 2017-12-15 株式会社钟根堂 作为cetp抑制剂的联芳基或杂环联芳基取代的环己烯衍生化合物
KR20160072265A (ko) * 2013-11-11 2016-06-22 론자 아게 (론자 엘티디.) 루이스 산을 갖는 13 족의 시아노 화합물의 제조 방법
SI3180314T1 (sl) * 2014-08-12 2022-11-30 Newamsterdam Pharma B.V. Postopek za pripravo sintetičnih intermediatov za pripravo derivatov tetrahidrokinolina
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935933T2 (de) 1998-07-10 2008-01-10 Massachusetts Institute Of Technology, Cambridge Liganden für Metalle und verbesserte Metall-katalysierte Verfahren, die darauf basieren
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
HUP0304039A3 (en) 2005-10-28
HUP0304041A2 (hu) 2004-04-28
CA2445693A1 (en) 2002-11-07
IL157546A0 (en) 2004-03-28
DK1425270T3 (da) 2006-07-03
CN1505609A (zh) 2004-06-16
PL366584A1 (en) 2005-02-07
CN1529696A (zh) 2004-09-15
RU2003131871A (ru) 2005-04-10
CN1680292A (zh) 2005-10-12
ATE316957T1 (de) 2006-02-15
AR044706A2 (es) 2005-09-21
EP1383734B1 (en) 2006-02-01
AR035963A1 (es) 2004-07-28
BR0209291A (pt) 2004-07-13
DE60210265T2 (de) 2006-10-12
PL366700A1 (en) 2005-02-07
ATE321755T1 (de) 2006-04-15
CZ20032898A3 (cs) 2004-07-14
ES2256461T3 (es) 2006-07-16
WO2002088069A2 (en) 2002-11-07
KR20040030603A (ko) 2004-04-09
HUP0304041A3 (en) 2005-08-29
WO2002088085A3 (en) 2004-03-25
TWI250974B (en) 2006-03-11
HU225777B1 (en) 2007-08-28
JP3924251B2 (ja) 2007-06-06
EP1425270B1 (en) 2006-03-29
JP2004527556A (ja) 2004-09-09
KR100639745B1 (ko) 2006-10-30
US6689897B2 (en) 2004-02-10
DK1383734T3 (da) 2006-05-15
US6600045B2 (en) 2003-07-29
IL157544A0 (en) 2004-03-28
EP1383734A2 (en) 2004-01-28
HUP0304039A2 (hu) 2004-03-29
DE60209004T2 (de) 2006-09-28
MXPA03009935A (es) 2004-01-29
EP1425270A2 (en) 2004-06-09
CN1297541C (zh) 2007-01-31
KR20040015200A (ko) 2004-02-18
CA2445623A1 (en) 2002-11-07
DE60209004D1 (de) 2006-04-13
JP3924250B2 (ja) 2007-06-06
WO2002088069A3 (en) 2003-02-20
ES2259080T3 (es) 2006-09-16
CN100357265C (zh) 2007-12-26
WO2002088069A9 (en) 2003-12-04
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
US20030073843A1 (en) 2003-04-17
RU2259355C2 (ru) 2005-08-27
ZA200306600B (en) 2004-08-25
RU2265010C2 (ru) 2005-11-27
YU84403A (sh) 2006-08-17
CZ20032900A3 (cs) 2004-06-16
ZA200306599B (en) 2004-10-22
DE60210265D1 (de) 2006-05-18
AU2002253448B2 (en) 2007-07-05
US20020177716A1 (en) 2002-11-28
KR100591998B1 (ko) 2006-06-22
CN1267411C (zh) 2006-08-02
JP2004531541A (ja) 2004-10-14
RU2003131870A (ru) 2005-01-27
US6706881B2 (en) 2004-03-16
PT1425270E (pt) 2006-07-31
WO2002088085A2 (en) 2002-11-07
MXPA03009936A (es) 2004-01-29
YU84303A (sh) 2006-05-25
US20030216576A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
HK1062294A1 (en) Compounds useful as intermediates for 4-aminoquinoline derivates
EP1451156A4 (en) 4-AMINOQUINOLINE COMPOUNDS
GB0105895D0 (en) Novel compounds
AU2002359165A8 (en) Novel compounds
GB0107907D0 (en) Novel compounds
GB0104259D0 (en) Novel compounds
GB0103866D0 (en) Novel compounds
GB0102470D0 (en) Novel compounds
GB0102713D0 (en) Novel compounds
GB0102714D0 (en) Novel compounds
GB0108365D0 (en) Novel compounds
GB0102469D0 (en) Novel compounds
GB0111571D0 (en) Novel compounds
GB0113812D0 (en) Novel compounds
GB0116944D0 (en) Novel Compounds
GB0119157D0 (en) Novel compounds
GB0102577D0 (en) Novel Compounds
GB0102576D0 (en) Novel compounds
GB0120691D0 (en) Novel Compounds
GB0102570D0 (en) Novel Compounds
GB0102578D0 (en) Novel Compounds
GB0101334D0 (en) Novel compounds
GB0119242D0 (en) Novel compounds
GB0101437D0 (en) Novel Compounds
GB0127936D0 (en) Novel compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100408